Calix Inc. (NYSE:CALX) shares moved down -0.41% in last trading session and ended the day at $7.26. CALX Gross Margin is 47.20% and its has a return on assets of -5.60%. Calix Inc. (NYSE:CALX) quarterly performance is -7.28%.
Calix, Inc. (NYSE: CALX) reported Q3 EPS of $0.16, $0.08 better than the analyst estimate of $0.08. Revenue for the quarter came in at $12.3 million versus the consensus estimate of $109.14 million. Our third quarter results were above our guidance, reflecting strong performance in our customer base for the quarter,” said Carl Russo, Calix President and CEO. “This performance contributed to revenues in the first nine months of 2015 increasing 4.4% compared to the first nine months of 2014. In addition, solid execution and favorable product mix led non-GAAP gross margins for the first nine months to increase to 49.8% compared to 46.1% in the same period last year,” added Russo.
Mannatech, Incorporated (NASDAQ:MTEX) ended the last trading day at $19.52. Company weekly volatility is calculated as 8.23% and price to cash ratio as 1.70. Mannatech, Incorporated (NASDAQ:MTEX) showed a weekly performance of -29.28%.
Mannatech, Incorporated (NASDAQ: MTEX), the founder of the M5M℠ (Mission 5 Million℠) Foundation, the pioneer of nutritional glycobiology and the global innovator of naturally sourced supplements based on Real Food Technology® solutions, will officially launch its newest brain health product, Cognitate, on October 31 in Korea.
On 10 November, El Paso Electric Co. (NYSE:EE) shares advanced 1.71% and was closed at $39.89. EE EPS growth in last 5 year was 8.60%. El Paso Electric Co. (NYSE:EE) year to date (YTD) performance is 2.09%.
El Paso Electric Co. (NYSE:EE) Announces Third Quarter Financial Results. For the third quarter of 2015, El Paso Electric Company (“EE” or the “Company”) reported net income of $56.7 million, or $1.40 basic and diluted earnings per share. In the third quarter of 2014, EE reported net income of $52.5 million, or $1.30 basic and diluted earnings per share. For the nine months ended September 30, 2015, EE reported net income of $81.3 million, or $2.01 basic and diluted earnings per share. Net income for the nine months ended September 30, 2014 was $87.2 million, or $2.16 basic and diluted earnings per share.
EMC Corporation (NYSE:EMC) shares moved down -2.25% in last trading session and ended the day at $25.25. EMC Gross Margin is 61.20% and its has a return on assets of 5.30%. EMC Corporation (NYSE:EMC) quarterly performance is -3.81%.
EMC Corporation (EMC) reported that Nina Hargus has been designated Chief Marketing Officer of EMC Information Infrastructure, effective immediately. She will be responsible for the global structure, strategy, and execution of all aspects of EMC Information Infrastructure’s marketing efforts, reporting to Jeremy Burton (@jburton). Burton has been serving as interim CMO since June 2015, and will continue in his role as President of Products and Marketing of EMC Information Infrastructure. Hargus has held the position of CMO at VCE for the last three years and, as the head of the VCE marketing team, will continue to play an integral role in the VCE business driving thought leadership, growth and market leadership.
Gilead Sciences Inc. (NASDAQ:GILD) caters to the Healthcare space. It has a net profit margin of 53.80% and weekly performance is -0.23%. On the last day of trading company shares ended up at $108.85. Gilead Sciences Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 0.98%.
Gilead Sciences Inc. (NASDAQ:GILD) said the U.S. Food and Drug Administration approved the biotech company’s single tablet regimen treatment for HIV-1 infection.Genvoya is the first drug with tenofovir alafenamide, or TAF, to receive FDA approval.Chief Executive John Martin said Genvoya is the first in a portfolio of TAF-based products that has the potential to advance the long-term treatment of HIV. While exceptional progress has been made in the field of HIV, there is still a need for new treatment options that may help improve the health of people as they grow older with the disease,” he said.